MarginsXMarginsX
Home › Markets › Health Care › CRVS

Corvus Pharmaceuticals Inc. (CRVS)

CRVS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.60
-0.38% on the day
Market cap
$894.1M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCRVS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001626971
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
3.8 months
$15.0M cash at September 30, 2026
Share count, 1 year
+12.9%
2025-11-04 to 2026-11-05 · +72.0% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$334K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with applicable accounting standards, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date of the issuance of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and concluded that our existing cash,"
10-Q 2026-11-05
Cash and burn$15.0M cash; operating cash flow -$11.8M a quarter.Report 2026-09-30
Shares outstanding84,353,126 (2026-11-05); 74,681,872 a year earlier; 49,038,582 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-03-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $334K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$20.3M-$12.2M$15.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$18.0M-$15.4M$18.9MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$13.7M-$10.4M$40.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$12.3M-$9.2M$4.6MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$10.2M-$9.6M$2.9MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$8.0M-$5.8M$14.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed$15.2M-$8.3M$5.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$12.1M-$8.5M$8.7MNo debt tagsNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-13
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 585 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.9%
1 month+13.1%
3 months-29.7%
Year to date+38.2%
1 year+33.0%
From 52-week high-58.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PHARPharming Group N.V. ADS each representing 10$12.59-0.08%$889.2M
AKTSAktis Oncology Inc.$16.16-2.77%$901.7M
CTYCity Therapeutics Inc.$16.98-6.19%$854.6M
LTGOLatigo Biotherapeutics Inc.$12.60-3.89%$835.4M
VSTMVerastem Inc.$7.70-5.87%$970.3M
RIGLRigel Pharmaceuticals Inc.$43.73-1.64%$823.4M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier